prIME Conference on Colorectal Cancer
prIME Conference
prIME Conference

prIME Conference on Colorectal Cancer

Current and Emerging Strategies in Multidisciplinary Management

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

prIME Conference on Colorectal Cancer: Current and Emerging Strategies in Multidisciplinary Management will update you with the latest advances in the management of colorectal cancer (CRC) and will provide you with guidance on how to best implement new evidence into clinical practice to improve patient outcomes and quality of life. In addition to extensive evaluation of clinical and molecular biomarkers and systemic treatment options, this conference also offers a practical perspective on how to optimize multidisciplinary care that requires complex clinical treatment decisions and integrate locoregional treatment modalities into different clinical situations.

Date and Location

Saturday, 20 April 2019
08.00 – 17.20

Room: Infinity Ballroom
Hilton Beijing
1 Dong Fang Rd
North Dongsanhuan Rd
Beijing, China

Date/Time

Date/Time

Saturday, 20 April 2019
08.00 – 17.20

Location

Location

Beijing, China

08.00 Registration and welcome coffee
08.30 Introduction and demographics
Dirk Arnold, MD, PhD; Ruihua Xu, MD, PhD; and Bojana Pajk, MD, MSc (prIME Medical Director)
08.40 Quiz: Are you up to date with advances in CRC management?
08.50 Accomplishments and challenges in the management of CRC in Asia
Ying Yuan, MD, PhD
09.15 Q & A
09.25 Keynote presentation—Precision therapy for CRC in the era of next-generation sequencing
Julien Taïeb, MD, PhD
09.50 Q & A
10.00 Coffee break
10.20 Latest recommendations for multidisciplinary management of CRC liver metastases
Eiji Oki, MD, PhD, FACS
10.50 Commentary: Is cure possible in patients with unresectable colorectal liver metastases?
Jianmin Xu, MD, PhD
11.05 Q & A
11.15 Clinical cases of CRC with oligometastatic metastases: Challenging questions for the multidisciplinary team
Moderator: Jianmin Xu, MD, PhD
12.15 Lunch
13.15 Planning treatment for RAS-wildtype mCRC: First-line and across disease continuum
Jun Zhang, MD, PhD
13.40 Q & A
13.50 Managing BRAF-mutant mCRC in 2019: Maximizing targeted therapy approaches
Dirk Arnold, MD, PhD
14.10 Q & A
14.20 Clinical cases of mCRC: Challenging questions for the multidisciplinary team
Moderator: Ruihua Xu, MD, PhD
15.00 Coffee break
15.20 Liquid biopsy in CRC: Clinical applications
Ruihua Xu, MD, PhD
15.40 Q & A
15.50 Updates on immunotherapy in mCRC: Current status and ongoing efforts
Li-Tzong Chen, MD, PhD
16.10 Q & A
16.15 Total neoadjuvant therapy: A novel strategy for locally advanced rectal cancer
Hiroya Taniguchi, MD, PhD
16.35 Q & A
16.40 Clinical case of rectal cancer: Challenging questions for the multidisciplinary team
Moderator: Dirk Arnold, MD, PhD
17.00 Quiz questions revisited and faculty commentary
17.15 prIME Points™
Dirk Arnold, MD, PhD, and Ruihua Xu, MD, PhD
17.20 Adjourn

    Co-Chairs

  • Dirk Arnold, MD, PhDAsklepios Clinic Altona
    Hamburg, Germany
  • Ruihua Xu, MD, PhDSun Yat-sen University Cancer Center
    Guangzhou, China
  • Faculty

  • Li-Tzong Chen, MD, PhDNational Institute of Cancer Research
    National Health Research Institutes
    Taipei, Taiwan
  • Eiji Oki, MD, PhD, FACSKyushu University
    Fukuoka, Japan
  • Julien Taïeb, MD, PhD Georges Pompidou European Hospital
    Paris, France
  • Hiroya Taniguchi, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan
  • Jianmin Xu, MD, PhDZhongshan Hospital
    Fudan University
    Shanghai, China
  • Yuan Ying, MD, PhDThe Second Affiliated Hospital
    Zhejiang University School of Medicine
    Zhejiang, China
  • Jun Zhang, MD, PhDRuijin Hospital
    Shanghai Jia Tong University
    Shanghai, China

This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals involved in the management of CRC in the Asia Pacific (APAC) region.

After successful completion of this educational activity, participants should be able to:

  • Evaluate current and emerging biomarkers to guide precision medicine in metastatic CRC (mCRC) and the potential role of liquid biopsy in the management of early and metastatic CRC
  • Select multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with oligometastatic disease (eg, liver-only metastases)
  • Determine the best front-line therapy for mCRC based on patient and tumor characterisitcs and assess treatment beyond disease progression
  • Identify therapeutic options for BRAF-mutant mCRC
  • Explain treatment options for locally advanced rectal cancer
  • Describe emerging agents and treatment strategies in mCRC including the role of immunotherapy in mCRC and anti-EGFR rechallenge

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Continuing Education

An application has been made to the EACCME® for CME Accreditation of this event.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosures

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.